

NEW ZEALAND DATA SHEET

1. PRODUCT NAME

SEREVENT Inhaler (CFC-Free); 25 micrograms, aerosol inhaler, metered dose

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

SEREVENT Inhaler is a pressurised metered-dose inhaler delivering 25 micrograms salmeterol as salmeterol xinafoate with each actuation.

For full list of excipients, see section 6.1 List of excipients.

3. PHARMACEUTICAL FORM

Aerosol inhaler, metered dose.

SEREVENT Inhaler (CFC-Free) consists of a white microfine suspension of salmeterol as salmeterol xinafoate (salmeterol hydroxynaphthoate) in a chlorofluorohydrocarbon (CFC)-free liquid propellant, norflurane, packed under its own vapour pressure in an aluminium can which is sealed with a metering valve.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Asthma

SEREVENT is indicated for long-term regular treatment of reversible airways obstruction in asthma (including nocturnal asthma and exercise-induced asthma) in adults and children aged 4 years and over who are receiving inhaled or oral corticosteroids.

SEREVENT should be used only as an adjunct to corticosteroids in the management of asthma.

SEREVENT should not be used in the treatment of acute asthmatic symptoms, or in patients whose asthma can be managed by occasional use of short-acting beta-2 agonists.

Chronic Obstructive Pulmonary Disease (COPD)

SEREVENT is indicated for long-lasting (12 hour) bronchodilatation in adults with reversible airways obstruction due to (COPD)

4.2 Dose and method of administration

Dose

SEREVENT is administered by the inhaled route only.

Patients must be warned not to stop therapy or reduce it without medical advice, even if they feel better on SEREVENT.

Asthma

In the management of reversible airways obstruction due to asthma, SEREVENT (as with other long-acting beta-2 agonists, **must only be administered in combination with anti-inflammatory therapy such as inhaled corticosteroids (ICS)**). In asthma patients not already receiving anti-inflammatory therapy, this must be initiated at the same time as SEREVENT.

Adults:

Two inhalations (2 x 25 micrograms of salmeterol) twice daily.

In asthma patients with more severe airways obstruction up to four inhalations (4 x 25 micrograms of salmeterol) twice daily may be of benefit.

Children over 4 years of age:

Two inhalations (2 x 25 micrograms of salmeterol) twice daily.

There are insufficient clinical data at present to recommend the use of SEREVENT in children under 4 years of age.

Patients should be instructed not to take additional doses to treat symptoms but to take a short-acting inhaled beta-2 agonist.

The onset of effective bronchodilation (>15% improvement in FEV₁) with SEREVENT occurs within 10 to 20 minutes in asthma patients. The full benefits will be apparent after the first few doses of the drug. The bronchodilator effects of SEREVENT usually last for 12 hours. This is particularly useful in the treatment of nocturnal symptoms in asthma, COPD and chronic bronchitis and in the management of exercise induced asthma.

As there may be adverse effects associated with excessive dosing of this class of drug, the dosage of frequency of administration should only be increased on medical advice.

COPD

Adults:

Two inhalations (2 x 25 micrograms of salmeterol) twice daily.

Special populations

There is no need to adjust the dose in elderly patients or in those with renal impairment.

In patients who find co-ordination of a pressurised metered-dose inhaler difficult a spacer device may be used with SEREVENT Inhaler (CFC-Free).

Method of administration

For instructions on the use and handling of this medicine, see section 6.6 Special precautions for disposal and other handling.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 List of excipients.

4.4 Special warnings and precautions for use

SEREVENT should not be initiated in patients with unstable or acutely deteriorating asthma, which may be a life threatening condition. Serious acute respiratory events, including fatalities have been reported when salmeterol has been initiated in the situation. Although it is not possible from these reports to determine whether salmeterol contributed to these adverse events or failed to relieve the deteriorating asthma, the use of salmeterol in this setting is inappropriate.

Use with corticosteroids for asthma

SEREVENT is a long acting beta-2 agonist and should be used only as an adjunct to corticosteroids in the management of asthma. SEREVENT is not a replacement or substitute for oral or inhaled corticosteroids. Its use is complementary to them.

Patients must be warned not to stop or reduce corticosteroid therapy, even if they feel better. Any change in corticosteroid dosage should be made ONLY after clinical evaluation.

In asthma patients not already receiving anti-inflammatory therapy, this should be initiated when starting therapy with SEREVENT.

Data from a large US study (SMART) comparing the safety of salmeterol (50 micrograms inhaler twice daily) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol versus those on placebo (13 out of 13,176 vs 3 out of 13,179 over 28 weeks). Data from this study suggested that African-American patients may be at greater risk of serious respiratory-related events or deaths when using salmeterol compared to placebo. It is not known if this was due to pharmacogenetic or other factors. Patients on salmeterol who did not receive inhaled corticosteroids as part of their usual therapy at the start of the study experienced a greater number of asthma-related deaths compared to those taking placebo (9 out of 7,049 vs. 0 out of 7,041). There were no significant differences between the salmeterol and placebo treatment groups among patients who were receiving inhaled corticosteroids at the start of the study. Long-acting beta-2-agonists, such as salmeterol, should be prescribed with corticosteroids.

Acute asthma symptoms

SEREVENT is suitable for long-term regular, twice-daily treatment to control symptoms of reversible airways obstruction.

In view of its slower onset of action (10 to 20 minutes) it should not be used to relieve acute symptoms of asthma, for which a faster acting (within 5 minutes) inhaled bronchodilator (e.g. short-acting beta-2 agonists such as salbutamol) should be given.

It is crucial to inform patients of this and prescribe a short-acting inhaled beta-2 agonist for this purpose.

Deterioration of asthma control

Sudden and progressive deterioration of asthma control is potentially life threatening and considerations should be given to increasing corticosteroid therapy. In patients at risk, daily peak flow monitoring may be instituted.

Increasing use of bronchodilators, in particular short-acting inhaled beta-2 agonists, to relieve symptoms indicates deterioration of asthma control.

Severe exacerbations of asthma must be treated in the normal way with nebulised or parenteral bronchodilators and parenteral corticosteroids, together with other supportive measures.

As with other inhalational therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing. This should be treated immediately with a fast-acting inhaled bronchodilator. SEREVENT should be discontinued immediately, the patient assessed, and if necessary alternative therapy instituted.

The pharmacological side-effects of beta-2 agonist treatment, such as tremor, subjective palpitations and headache have been reported, but tend to be transient and to reduce with regular therapy.

Cardiovascular effects, such as increases in systolic blood pressure and heart rate, may occasionally be seen with all sympathomimetic drugs, especially at higher than therapeutic doses. For this reason, SEREVENT should be used with caution in patients with pre-existing cardiovascular disease.

Spacer Devices

Patients' inhaler technique should be checked to make sure that aerosol actuation is synchronised with inspiration of breath for optimum delivery of the drug to the lungs.

Most patients will benefit from the consistent use of a spacer device with their inhaler ('puffer'), particularly those with poor inhaler technique. Use of a spacer will also decrease the amount of drug deposited in the mouth and back of the throat, and therefore reduce the incidence of local side effects such as 'thrush' and a hoarse voice.

A change in the make of spacer may be associated with alterations in the amount of drug delivered to the lungs. The clinical significance of these alterations is uncertain. However, in these situations, the person should be monitored for any loss of asthma control.

If using a spacer, the patient should be instructed to actuate the inhaler into the spacer and then slowly breathe in as far as possible. Hold your breath for as long as comfortable, before breathing out slowly. This should be repeated for each actuation of the drug into the spacer. Any delays between actuation and inhalation should be kept to a minimum.

Static on the walls of the spacer may cause variability in drug delivery. Patients should be instructed to wash the spacer in warm water and detergent and allow it to air dry without rinsing or drying with a cloth. This should be performed before initial use of the spacer and at least monthly thereafter.

Other special populations

There have been very rare reports of increases in blood glucose levels (see section 4.8 Undesirable Effects) and this should be considered when prescribing to patients with a history of diabetes mellitus.

SEREVENT should be administered with caution in patients with thyrotoxicosis.

A transient decrease in serum potassium may occur with all sympathomimetic drugs at higher therapeutic doses. Therefore, SEREVENT should be used with caution in patients predisposed to low levels of serum potassium.

4.5 Interaction with other medicines and other forms of interaction

Both non-selective and selective beta-blockers should be avoided in patients with reversible obstructive airways disease, unless there are compelling reasons for their use.

Co-administration of ketoconazole and salmeterol resulted in a significant increase in plasma salmeterol exposure (1.4-fold C_{max} and 15-fold AUC) to prolongation of the QTc interval (see section 4.4 Special warnings and precautions for use and 5.2 Pharmacokinetic properties).

It was observed in a drug interaction study that concomitant use of systemic ketoconazole increases exposure to salmeterol. This may lead to prolongation in the QTc interval. Caution must be exercised when strong CYP3A4 inhibitors (eg ketoconazole) are co-administered with salmeterol (see section 5.2 Pharmacokinetic properties).

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no adequate and well controlled studies of salmeterol in pregnant women. The effect of salmeterol on human pregnancy is unknown.

As with any medicine, use of SEREVENT during pregnancy should be considered only if the expected benefit to the mother is greater than any possible risk to the foetus.

In animal studies, some effects on the foetus, typical for a beta-2 agonist, occurred at exposure levels substantially higher than those that occur with therapeutic use. Extensive experience with other beta-2 agonists has provided no evidence that such effects are relevant for women receiving clinical doses.

Breast-feeding

Plasma levels of salmeterol after inhaled therapeutic doses are negligible and therefore levels in milk should be correspondingly low. Nevertheless as there is limited experience of the use of salmeterol in nursing mothers its use in such circumstances should only be considered if the expected benefit to the mother is greater than any possible risk to the infant.

Studies in lactating animals support the view that salmeterol is likely to be secreted in only very small amounts into breast milk.

Fertility

There are no data on human fertility

4.7 Effects on the ability to drive and use machines

None reported.

4.8 Undesirable effects

Summary of the safety profile

Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common ($\geq 1/10$), common ($\geq 1/100$ to $<1/10$), uncommon ($\geq 1/1000$ to $<1/100$), rare ($\geq 1/10,000$ to $<1/1000$) and very rare ($<1/10,000$) including isolated reports. Common and uncommon events were generally determined from clinical trial data. The incidence of placebo was not taken into account. Very rare events were generally determined from post-marketing spontaneous data.

The following frequencies are estimated at the standard dose of 50 micrograms twice daily. Frequencies at the higher dose of 100 micrograms twice daily have also been taken to account where appropriate.

Tabulated list of adverse events

Immune system disorders

Hypersensitivity Reactions:

Uncommon: Rash.

Very rare: Anaphylactic reactions including oedema and angioedema, bronchospasm and anaphylactic shock.

Metabolism and nutrition disorders

Very rare: Hyperglycaemia.

Nervous system disorders

Common: Tremor and headache (see section 4.4 Special warnings and precautions for use).

The pharmacological side-effects of beta-2 agonist treatment, such as tremor and headache have been reported, but tend to be transient and to reduce with regular therapy. Tremor occurs more commonly when administered at doses higher than 50 micrograms twice daily.

Cardiac disorders

Common: Palpitations (see section 4.4 Special warnings and precautions for use).

Uncommon: Tachycardia.

Tachycardia occurs more commonly when administered at doses higher than 50 micrograms twice daily.

Very rare: Cardiac arrhythmias including atrial fibrillation, supraventricular tachycardia and extrasystoles.

Respiratory, thoracic and mediastinal disorders

Very rare: Oropharyngeal irritation and paradoxical bronchospasm (see section 4.4 Special warnings and precautions for use).

Musculoskeletal and connective tissue disorders

Common: Muscle cramps.

Very rare: Arthralgia.

Reporting of suspected adverse reactions

Reporting of suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via: <https://nzphvc.otago.ac.nz/reporting/>

4.9 Overdose

The expected symptoms and signs of salmeterol overdosage are those typical of excessive beta-2-adrenergic stimulation, including tremor, headache, tachycardia, increases in systolic blood pressure and hypokalaemia and raised blood glucose levels.

If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary. Further management should be as clinically indicated or as recommended by the Poison Information Centre.

Propellant

As with many other pressurised aerosol formulations, salmeterol metered aerosol contains fluorocarbon propellants. In large doses these propellants can produce cardiac arrhythmia in animals as well as sensitise their hearts to adrenaline induced arrhythmia.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Selective beta-2-adrenoreceptor agonists,

ATC code: R03AC12

Mechanism of action

Salmeterol is a selective long-acting (12 hour) beta-2 adrenoceptor agonist with a long side-chain which binds to the exo-site of the receptor.

These pharmacological properties of salmeterol offer more effective protection against histamine-induced bronchoconstriction and produce a longer duration of bronchodilation, lasting for at least 12 hours, than recommended doses of conventional short-acting beta-2 agonists. *In vitro* tests have shown salmeterol is a potent and long-lasting inhibitor of the release, from human lung, of mast cell mediators, such as histamine, leukotrienes and prostaglandin D₂. In man salmeterol inhibits the early and late phase response to inhaled allergen; the latter persisting for over 30 hours after a single dose when the bronchodilator effect is no longer evident. Single dosing with salmeterol attenuates bronchial hyper-responsiveness. These properties indicate that SEREVENT has additional non-bronchodilator activity, but the full clinical significance is not yet clear. The mechanism is different from the anti-inflammatory effect of corticosteroids, which should not be stopped or reduced when SEREVENT is prescribed.

SEREVENT has been studied in the treatment of conditions associated with COPD and has been shown to improve symptoms and pulmonary function, and quality of life. Salmeterol acts as a beta-2 agonist on the reversible component of the disease. *In vitro* salmeterol has also been shown to increase ciliary beat frequency of human bronchial epithelial cells, and also reduce acidotoxic effect of *Pseudomonas* toxin on the bronchial epithelium of patients with cystic fibrosis.

5.2 Pharmacokinetic properties

SEREVENT acts locally in the lung therefore plasma levels are not predicative of therapeutic effect. In addition there are only limited data available on the pharmacokinetics of salmeterol because of the technical difficulty of assaying the drug in plasma because of the very low plasma concentrations (approximately 200pg/mL or less) achieved after inhaled dosing. After regular dosing with SEREVENT xinafoate, hydroxynaphthoic acid can be detected in the systemic circulation, reaching steady state concentrations of approximately 100ng/mL. These concentrations are up to 1000 fold lower than steady state levels observed in toxicity studies and in long term regular dosing (more than 12 months) in patients with airways obstruction, have been shown to produce no ill effects.

In a placebo-controlled, crossover drug interaction study in 15 healthy subjects, co-administration of salmeterol (50 micrograms twice daily inhaled) and the CYP3A4 inhibitor ketoconazole (400 mg once daily orally) for 7 days resulted in a significant increase in plasma salmeterol exposure (1.4-fold C_{max} and 15-fold AUC). There was no increase in salmeterol accumulation with repeat dosing. Three subjects were withdrawn from salmeterol and ketoconazole co-administration due to QTc prolongation or palpitations with sinus tachycardia. In the remaining 12 subjects, co-administration of salmeterol and ketoconazole did not result in a clinically significant effect on heart rate, blood potassium or QTc duration (see section 4.4 Special warnings and precautions for use and 4.5 Interactions with other medicines and other forms of interaction).

An *in vitro* study showed that salmeterol is extensively metabolised to α -hydroxysalmeterol (aliphatic oxidation) by cytochrome P450 3A4 (CYP3A4). A repeat dose study with salmeterol and erythromycin in healthy volunteers showed no clinically significant changes in pharmacodynamic effects at 500 mg three times daily doses of erythromycin.

5.3 Preclinical safety data

In reproduction studies in animals, some effects on the foetus, typical of a beta-2 agonist, have been observed at very high doses.

Salmeterol xinafoate produced no genetic toxicity in a range of studies using either prokaryotic or eukaryotic cell systems *in vitro* or *in vivo* in the rat.

Long term studies with salmeterol xinafoate, induced class related benign tumours of smooth muscle in the mesovarium of rats and the uterus of mice.

The scientific literature and our own pharmacological studies provide good evidence that these effects are species specific and have no relevance for clinical use.

Carcinogenicity

Oral administration of salmeterol xinafoate to mice at 0.2, 1.4 or 10 mg/kg/day for 18 months resulted in the development of smooth muscle tumours (leiomyomas and possibly leiomyosarcomas) in the uterus. In rats, combined oral/inhalational administration for 24 months at total dose levels of 0.2, 0.7 and 2.6 mg/kg/day resulted in leiomyomas in the suspensory ligament of the ovaries, as well as an increased incidence of benign pituitary tumours. The smooth muscle tumours in both species are thought to result from chronic stimulation of beta-adrenoceptors in these tissues, whereas the mechanism involved in the development of the pituitary tumours is unknown.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Norflurane (also known as HFA 134a or 1,1,1,2-tetrafluoroethane).

6.2 Incompatibilities

None reported.

6.3 Shelf life

2 years.

6.4 Special precautions for storage

Store below 30°C

Replace the mouthpiece cover firmly and snap it into position.

Protect from frost and direct sunlight.

As with most inhaled medications in pressurised metered-dose inhalers, the therapeutic effect of this medication may decrease when the canister is cold.

The canister should not be broken, punctured or burnt, even when apparently empty.

6.5 Nature and contents of container

SEREVENT Inhaler (CFC-Free) is a pressurised metered-dose inhaler with a specially designed actuator. The container is an aluminium alloy canister fitted with a metering valve. Each canister provides 120 actuations.

6.6 Special precautions for disposal and other handling

Instructions for use:

1. Remove the mouthpiece cover by gently squeezing the sides of the cover.
2. Check inside and outside of the inhaler including the mouthpiece for the presence of loose objects.
3. Shake the inhaler well to ensure that any loose objects are removed and that the contents of the inhaler are evenly mixed.
4. Hold the inhaler upright between fingers and thumb with your thumb on the base, below the mouthpiece.
5. Breathe out as far as is comfortable and then place the mouthpiece in your mouth between your teeth and close your lips around it but do not bite it.
6. Just after starting to breathe in through your mouth press down on the top of the inhaler to release SEREVENT while still breathing in steadily and deeply.
7. While holding your breath, take the inhaler from your mouth and take your finger from the top of the inhaler. Continue holding your breath for as long as is comfortable.
8. If you are to take a further puff keep the inhaler upright and wait about half a minute before repeating steps 3 to 7.
9. After use always replace the mouthpiece cover to keep out dust and fluff.
10. Replace the mouthpiece cover by firmly pushing and snapping the cap into position.

Any unused medicinal product or waste should be disposed of in accordance with local requirement

7. MEDICINE SCHEDULE

Prescription Medicine

8. SPONSOR DETAILS

GlaxoSmithKline NZ Limited

Private Bag 106600
Downtown
Auckland
NEW ZEALAND

Phone: (09) 367 2900
Fax: (09) 367 2910

9. DATE OF FIRST APPROVAL

31 August 1995

10. DATE OF REVISION OF THE TEXT

5 December 2018

Summary table of changes:

Section changed	Summary of new information
All	Data Sheet re-format to comply with SmPC style format
4.1	Addition of age range to the indication
4.8	Addition of Adverse Event reporting instructions
5.1	Addition of Pharmacotherapeutic group and ATC code
6.6, 9, 10	Addition of these sections
10	Modification of copyright trademark and statements

Version: 5.0

Trademarks are owned by or licensed to the GSK group of companies.

© 2018 GSK group of companies or its licensor.